Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $180 from $167 and keeps an Overweight rating on the shares. The firm has updated its model for the quarter and adjusted its operating expense view, noting that Jazz is expected to announce its Q3 earnings call in early November.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Positive Outlook for Jazz Pharmaceuticals: Oncology Launches and Strategic Moves Drive Buy Recommendation
- Jazz Pharmaceuticals Completes Study on Promising HER2 Cancer Treatment
- Jazz Pharmaceuticals price target raised to $230 from $225 at BofA
- Jazz Pharmaceuticals announces FDA approves Zepzelca in ES-SCLC
- FDA approves combo of Jazz’s lurbinectedin and Roche’s atezolizumab for ES-SCLC